The Seagen and Genmab antibody drug conjugate (ADC), named Tivdak, is approved to treat cases of cervical cancer that have returned or spread following treatment with chemotherapy. Tivdak is Seagen’s third ADC; for Genmab, the drug will become its first commercialized product.
Novo Nordisk is paying $100 million up front to acquire an experimental Prothena drug being developed to treat heart problems stemming from a misfolded protein. The deal is part of a broader strategy to expand into drugs for cardiovascular disease.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Orphazyme’s corporate restructuring comes less than two weeks after the FDA rejected arimoclomol, a drug developed to treat the rare Niemann-Pick disease type C. The company said it is now focused on securing regulatory approval in Europe and finding a path forward for the small molecule with the FDA.
The list of FDA-approved antibody drug conjugates (ADC) is growing, and two more biotech startups have emerged from stealth with new cash and new approaches to this type of cancer drug. Adcendo and Adcentrx raised a combined $112 from their Series A financings.
Instead of suggesting a diagnosis for moles and skin lesions, digital health startup Miiskin is leaving that up to dermatologists. The company is rolling out a version of its tool for clinicians to make it easier for their patients to track moles and other spots on their skin.
The deal, which includes a hefty $750 million upfront payment to Genmab, focuses on bispecific antibodies and also a drug discovery research partnership.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The agency announced the approval of Bavarian Nordic's Jynneos. A 2003 outbreak in the Midwest marked the first time monkeypox was found outside of its native Africa. Smallpox has been eradicated, but bioterrorism concerns remain.
The drug, Rybelsus, is the first oral medication in the GLP-1 receptor agonist class. The approval was based on data from 10 trials that enrolled more than 9,500 patients.
Alder, based in a suburb of Seattle, has a monoclonal antibody that it has investigated as a treatment for migraine and is under FDA review, with the agency expected to decide on its approval in February of next year. Shares of Alder were up 83 percent on the news.
The company, whose FDA-approved products include the myeloma drug Darzalex and the chronic leukemia drug Arzerra, hopes to launch its own proprietary product by 2025.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
The idea behind the partnership is that consumers will be able to use their Android devices without relying on an intermediate tool for streaming audio to their hearing aids.
Financial terms are undisclosed, but CEO says acquisition is second largest after 2016 Astellas dermatology purchase.
The deal gives the Danish pharmaceutical company a consumer-focused technology platform to build on. In return, Glooko gains access to Novo Nordisk's extensive customer base and deep library of educational content.
It’s likely that lower-end versions will be made available over the coming years, but how long is that?
It’s no secret that big pharma has been getting leaner, with companies buying and selling businesses to play to their strengths. Novo Nordisk‘s plans to spin off its IT solutions business, NNIT, fits that pattern too. Although it announced intentions to review this option earlier this year, a few different press organizations, including Reuters, have […]